New Opportunities for Kinase Drug Repurposing and Target Discovery

Overview

Journal Br J Cancer

Specialty Oncology

Date 2018 Mar 17

PMID 29545596

Citations 17

Authors

Stefan Knapp

Affiliations

Soon will be listed here.

Abstract

Protein kinases are major drug targets for oncology. The large size of the kinome, active site conservation and the influence of activation states on drug binding complicates the analysis of their cellular mode of action. In a recent article in Science, Klaeger et al. analysed cellular targets of 243 drug candidates providing a large repository of data for drug repurposing.

Citing Articles

A comprehensive exploration of the druggable conformational space of protein kinases using AI-predicted structures.

Herrington N, Li Y, Stein D, Pandey G, Schlessinger A PLoS Comput Biol. 2024; 20(7):e1012302.

PMID: 39046952 PMC: 11268620. DOI: 10.1371/journal.pcbi.1012302.

TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro.

Duan Q, Wang H, Su W, Gu X, Shen X, Jiang Z BMC Med. 2024; 22(1):96.

PMID: 38443977 PMC: 10916235. DOI: 10.1186/s12916-024-03314-1.

Current trends and future prospects of drug repositioning in gastrointestinal oncology.

Fatemi N, Karimpour M, Bahrami H, Zali M, Chaleshi V, Riccio A Front Pharmacol. 2024; 14:1329244.

PMID: 38239190 PMC: 10794567. DOI: 10.3389/fphar.2023.1329244.

Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition.

Islam S, Rahaman M, Yu M, Noll B, Martin J, Wang S Cancers (Basel). 2023; 15(4).

PMID: 36831387 PMC: 9954146. DOI: 10.3390/cancers15041044.

Combined and Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells.

Islam S, Teo T, Kumarasiri M, Slater M, Martin J, Wang S Pharmaceuticals (Basel). 2022; 15(10).

PMID: 36297298 PMC: 9607353. DOI: 10.3390/ph15101186.

References

Fabian M, Biggs 3rd W, Treiber D, Atteridge C, Azimioara M, Benedetti M . A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005; 23(3):329-36. DOI: 10.1038/nbt1068. View

Yakes F, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P . Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011; 10(12):2298-308. DOI: 10.1158/1535-7163.MCT-11-0264. View

Fabbro D, Cowan-Jacob S, Moebitz H . Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol. 2015; 172(11):2675-700. PMC: 4439867. DOI: 10.1111/bph.13096. View

Ciceri P, Muller S, OMahony A, Fedorov O, Filippakopoulos P, Hunt J . Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol. 2014; 10(4):305-12. PMC: 3998711. DOI: 10.1038/nchembio.1471. View

Vasta J, Corona C, Wilkinson J, Zimprich C, Hartnett J, Ingold M . Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement. Cell Chem Biol. 2017; 25(2):206-214.e11. PMC: 5814754. DOI: 10.1016/j.chembiol.2017.10.010. View

Karaman M, Herrgard S, Treiber D, Gallant P, Atteridge C, Campbell B . A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008; 26(1):127-32. DOI: 10.1038/nbt1358. View

Fedorov O, Marsden B, Pogacic V, Rellos P, Muller S, Bullock A . A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007; 104(51):20523-8. PMC: 2154464. DOI: 10.1073/pnas.0708800104. View

Elkins J, Fedele V, Szklarz M, Abdul Azeez K, Salah E, Mikolajczyk J . Comprehensive characterization of the Published Kinase Inhibitor Set. Nat Biotechnol. 2015; 34(1):95-103. DOI: 10.1038/nbt.3374. View

Medard G, Pachl F, Ruprecht B, Klaeger S, Heinzlmeir S, Helm D . Optimized chemical proteomics assay for kinase inhibitor profiling. J Proteome Res. 2015; 14(3):1574-86. DOI: 10.1021/pr5012608. View

10.

Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S . Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007; 25(9):1035-44. DOI: 10.1038/nbt1328. View

11.

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig P . The target landscape of clinical kinase drugs. Science. 2017; 358(6367). PMC: 6542668. DOI: 10.1126/science.aan4368. View

12.

Li Y, Tang H, Sun Z, Bungum A, Edell E, Lingle W . Network-based approach identified cell cycle genes as predictor of overall survival in lung adenocarcinoma patients. Lung Cancer. 2013; 80(1):91-8. PMC: 3595338. DOI: 10.1016/j.lungcan.2012.12.022. View